| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 10:06:53 UTC |
|---|
| Update Date | 2021-09-26 23:04:43 UTC |
|---|
| HMDB ID | HMDB0252259 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Fimasartan |
|---|
| Description | Fimasartan belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond. Fimasartan is a drug which is used for the treatment of hypertension and heart failure [a20319]. Fimasartan possesses a half-life of 9 to 16 hours, appropriate for daily dosing. Fimasartan is rapidly absorbed and has minimal accumulation in the body 7 days after administration. Fimasartan is a moderately basic compound (based on its pKa). Collectively, fimasartain leads to a reduction in blood pressure and alleviation of hypertensive symptoms. In blocking the AT1 receptor, fimasartan inhibits vasoconstriction, favouring vasodilation. After ARB administration, mice showed improved prognosis after a myocardial infarcation, though further studies still need to be done to assess fimasartan's specific effects on decreasing cardiovascular damage. This compound has been identified in human blood as reported by (PMID: 31557052 ). Fimasartan is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Fimasartan is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1 InChI=1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32) |
|---|
| Synonyms | |
|---|
| Chemical Formula | C27H31N7OS |
|---|
| Average Molecular Weight | 501.65 |
|---|
| Monoisotopic Molecular Weight | 501.23107982 |
|---|
| IUPAC Name | 2-(2-butyl-4-methyl-6-oxo-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide |
|---|
| Traditional Name | 2-(2-butyl-4-methyl-6-oxo-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pyrimidin-5-yl)-N,N-dimethylethanethioamide |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1 |
|---|
| InChI Identifier | InChI=1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32) |
|---|
| InChI Key | AMEROGPZOLAFBN-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Biphenyls and derivatives |
|---|
| Direct Parent | Biphenyls and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Biphenyl
- Phenyltetrazole
- Pyrimidone
- Hydropyrimidine
- Pyrimidine
- Azole
- Heteroaromatic compound
- Tetrazole
- Thioamide
- Lactam
- Azacycle
- Organoheterocyclic compound
- Thiocarboxylic acid amide
- Hydrocarbon derivative
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxide
- Organopnictogen compound
- Organic nitrogen compound
- Organic oxygen compound
- Thiocarbonyl group
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Predicted by Siyang on May 30, 2022 | 15.7621 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.27 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2225.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 223.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 227.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 176.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 194.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 498.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 557.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 146.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1437.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 544.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1654.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 345.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 407.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 253.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 231.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Fimasartan,1TMS,isomer #1 | CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C)C=C1 | 4384.1 | Semi standard non polar | 33892256 | | Fimasartan,1TMS,isomer #1 | CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C)C=C1 | 4255.4 | Standard non polar | 33892256 | | Fimasartan,1TMS,isomer #1 | CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C)C=C1 | 5798.9 | Standard polar | 33892256 | | Fimasartan,1TBDMS,isomer #1 | CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C(C)(C)C)C=C1 | 4495.0 | Semi standard non polar | 33892256 | | Fimasartan,1TBDMS,isomer #1 | CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C(C)(C)C)C=C1 | 4467.7 | Standard non polar | 33892256 | | Fimasartan,1TBDMS,isomer #1 | CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C(C)(C)C)C=C1 | 5697.5 | Standard polar | 33892256 |
|
|---|
| MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 10V, Positive-QTOF | splash10-0pb9-0030960000-dd2da35f51953b920d88 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 20V, Positive-QTOF | splash10-052r-0041910000-d7d17a66270a0f8c0b7c | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 40V, Positive-QTOF | splash10-000i-2292300000-87b2a341718ec4d2e006 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 10V, Negative-QTOF | splash10-0uxr-1141290000-aaa75614c4ae72f6104e | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 20V, Negative-QTOF | splash10-0gbi-6091640000-2dc2e62da582d11f5f1e | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 40V, Negative-QTOF | splash10-0ul9-5690000000-9f097c695a6f54d94514 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 10V, Positive-QTOF | splash10-0udi-0010090000-94eb40fd5ce79a8edf80 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 20V, Positive-QTOF | splash10-0zg0-0892710000-e7f60d4e8f8c0af615b3 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 40V, Positive-QTOF | splash10-0a4u-0691000000-bb24744f9b331ebec783 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 10V, Negative-QTOF | splash10-0udi-0000090000-ea30f579697b5176d928 | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 20V, Negative-QTOF | splash10-0ab9-2122900000-4d9ce23aea33794c025d | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fimasartan 40V, Negative-QTOF | splash10-0329-1950000000-9727206587cf26d4a1d1 | 2021-10-12 | Wishart Lab | View Spectrum |
|
|---|